{"name":"Novita Pharmaceuticals, Inc.","slug":"novita-pharmaceuticals-inc","ticker":"","exchange":"","domain":"novita.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Anti-PD-1 Therapy","genericName":"Anti-PD-1 Therapy","slug":"anti-pd-1-therapy","indication":"Non-small cell lung cancer","status":"phase_2"}]}],"pipeline":[{"name":"Anti-PD-1 Therapy","genericName":"Anti-PD-1 Therapy","slug":"anti-pd-1-therapy","phase":"phase_2","mechanism":"Inhibits PD-1 receptor","indications":["Non-small cell lung cancer","Melanoma","Head and neck cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNeUZsTVVMVzZ5TWlULVEzTW1PejNkODhMd3RQdFRRNDlLd214UE84ZERwbEprWl9WQWtHQzJhR18xdUYwQndtU3RqRExVUTV3UGpsOGVaR3JDbFl6OF9MNkJnc0Y1SmFJVTBjT1pobkpYVk9zdXZ0VVBScUIzdlFuZ2dXcHlIS2hRWmVFZDlWalEwcG81LTB2anpuVnQ3LVFvNmgzaGU2dklGYVRxOHViQXVoUE1wdHU5VTNyUXhIdUl2c2lxLTJKYnU3eTRYX1dZeE5Ua01RNVllMlptcEpTUVB6cFlKWEtTU1hNX2QxZVMyVTZTVVB4Tm0wOXZ6Z1BoYmhLZlpELUNIV1RNSFl4UVNyeEJmSWREUFlkRElGVUc?oc=5","date":"2026-03-02","type":"regulatory","source":"PR Newswire UK","summary":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPTjFuanFnZ0lpampJc0hyMEJCNFVrWG5pYnotQ0FfNkt3ZHh0c3U1WGxNRDZRUzNVakJzUkdtWTBZa0dlRF9IX29jbW9xYWI0bm9ZdmtLWFVIdE5CRnUxa0hGNzJwclk5UFhZeldGdlRmcnQwRU5vMWFwdko4SEwxYUozbUkwN3NoNW9uTk9RVU1Oc1VTU0RKUWtlc1d4T1NmVUFWUA?oc=5","date":"2026-03-02","type":"regulatory","source":"Oncology News Central","summary":"Oncology Drugs Fast-Tracked by the FDA in February 2026 - Oncology News Central","headline":"Oncology Drugs Fast-Tracked by the FDA in February 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNSTRKS2JNRzlFLXJXdVp4N0xmbWNaeHRPZXV6NW5NU1gyTGcyNjc2Q2Y4Wk9IVmZFb1hvVDNSdVd4OU9vNzRyWC1QVlV1SllNMjVFdHVXdTBPZTdFTlFCbW1pbl80a0J1WjNkRWZQUm52ZWdtUDF3WV9YdVBoU01vWHFfUUlla29DWlRENEVpTDBYNkZpVl9vYmluRjAySEM4UE40d25CQkV2QQ?oc=5","date":"2026-02-03","type":"regulatory","source":"Oncology News Central","summary":"Key Oncology Drugs Granted FDA Designations in January 2026 - Oncology News Central","headline":"Key Oncology Drugs Granted FDA Designations in January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPcWRYaVpuMVFqN1piRE52MU5jLVZzWTVIcW5lY3o5dXg0UzlkZzM0Uy1qYlIwalNuUUx0WXBpRnN3YmFZaUxfSWdxMnV4UGxraUlpNmpiZEw1TmZYMHlacWhYQ2hXRnduYUt4aGxMMkp0OUFNbkd5N0NKMUJFSDV3SkZnck9ia0g3UFdncERnR2NpeTVERzgwWFNtS21IcXBWS21LSG1RTlZWTDhRMkdoR3Y4T0haRU1kMld0cVhWaDVPWkpqb1NRTFFXWHdSOHc1NFYyWkgyaDgzNVRDclRMX2ZmeVh1c0lOaWFXM2RaNXFZMjRPOGRhdElZR1Jta2c4UnhSV2hQVQ?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Novita Pharmaceuticals Announces FDA Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer - PR Newswire","headline":"Novita Pharmaceuticals Announces FDA Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPOEFiTWQ0cTVxa05QSHlDMzN4ZjJxVWxCVXRKZmtod0tHSTY3X2M3ZC1sSkRMQ2lfRWFMVmx5TnY1OWZkemY2S19kb3pBdXpDRmZ3N0QwN0FQWEtTcWM2YXc5cC1sV0ZOWGNkX19SaF9tR2doOWRBUEFXR3VPeDNQRXVnWTMxWWN1Z20ya0ZpV19xU1ZrM0pvWEF0VHEtMDZmaVlyVlhZT0ctVG9vQ0tRMEdVQVhLN3hrTDhUWDBOWkFCb2o4c2hRVVRyWnlEd2VVV2xvRnpveXNDVS02RlV0dEU5VXpadmlCNUlUOWxXZVozX0E2aXNyNG5JWDZBbjdrZi13T3FMMzZhbGlVYzU3c0N5RVo4RmJRM1Y2T1dNc2xzYjIxdWFKcw?oc=5","date":"2025-05-22","type":"trial","source":"PR Newswire","summary":"Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at 2025 ASCO Annual Meeting - PR Newswire","headline":"Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPMUJISW5sTnRUYjlpdjJmN2N1ZVRFMGpXb3FvQV9jclV0U1czbUZaTTh5OEYtTXplNkQ1NWZJR2luLVp6aUY1Y2U2dlNhTWlLWl85QlpqSURtbnhpTHkybGhiNVBpZ1VrTW1Zb3lYNTU3cFJSTkE5X1g5ZVgzVEZ1RFBsN05Nb2NLMWxrNUE1QnJ1dUhjczNsYVhHSVVjcElnb1BGa0lFMmdWTGxmWm5OTDBhNWQ?oc=5","date":"2024-10-04","type":"pipeline","source":"citybiz","summary":"Novita Pharmaceuticals Appoints Stewart Campbell as Chief Executive Officer - citybiz","headline":"Novita Pharmaceuticals Appoints Stewart Campbell as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxPdmJPRzlMdExGZmJKQ1FES2NERFE2U1RDem5qaVdPdm9IdnhkbTF6bUk2b2tLeHJqdXh6Vkw3aUtiQWNFQ3NzX3p2RHdPM3NiV1M5NlBlem5tUkV1TUVfcGxpTFhvRHM0dVNxM0E1dXJFM3ZZdmdvWDcxZ0FvMkFsYmVSYmNQWGlHQnBmSEZjUWtsak9aYWlETFE4d1k0TXJXcEtxZ2ZDVi1SanBNSWRBQXltWFFKbzduTVJHNTFoV05DLVZVX29mSG5wZnpJYzhsZGtJVU9ncGhoZ2d0NU5WdGdra0RsckFKbzZveWZid0ttcUY3eTkxVERGaUgzY21tUmVRVUxHbnBIUQ?oc=5","date":"2018-03-21","type":"regulatory","source":"PR Newswire","summary":"Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis - PR Newswire","headline":"Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Ps","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}